1-4 of 4
Marilyn J. Siegel
Close
Sort by
Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD
Journal: Blood
Blood (2012) 120 (21): 1623.
https://doi.org/10.1182/blood.V120.21.1623.1623
Published: 2012
Journal Articles

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J. Siegel, Amanda F. Cashen, Kristie A. Blum, Timothy S. Fenske, David D. Hurd, Andre Goy, Stephanie E. Schneider, Catherine R. Keppel, Nina D. Wagner-Johnston, Kenneth R. Carson, Nancy L. Bartlett
Journal: Blood
Blood (2011) 118 (19): 5119–5125.
https://doi.org/10.1182/blood-2011-07-362475
Published: 2011
Includes: Supplemental data
Journal Articles

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

Todd A Fehniger, MD, PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, Amanda F Cashen, MD, Kristie A Blum, MD, Timothy S. Fenske, MD, David D Hurd, MD, Andre Goy, MD, John F. DiPersio, MD, PhD, Nancy L Bartlett, MD
Journal: Blood
Blood (2009) 114 (22): 3693.
https://doi.org/10.1182/blood.V114.22.3693.3693
Published: 2009
Journal Articles

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

Todd A Fehniger, MD, PhD, Sarah Larson, BA, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, John F DiPersio, MD, PhD, Amanda F Cashen, MD, David D Hurd, MD, Kristie A Blum, MD, Nancy L Bartlett, MD
Journal: Blood
Blood (2008) 112 (11): 2595.
https://doi.org/10.1182/blood.V112.11.2595.2595
Published: 2008